Zhitong Finance App News, Junshi Biotech (688180.SH) announced that Topuaili Biopharmaceutical Hong Kong Co., Ltd., a wholly-owned subsidiary of the company, has obtained the “Drug/Product Registration Certificate” issued by the Hong Kong Pharmacy and Poison Administration (“PPB”), and treprilimab (Hong Kong, China trade name: LOQTORZI®) combined with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent advanced nasopharyngeal cancer, and as a monotherapy for the recurrence and non-recurrence of disease progression after prior platinum-containing treatment or treatment or metastatic nasopharyngeal cancer The marketing license application for adult patients has been approved by PPB, and treprilizumab became the first and only tumor immunotherapy for nasopharyngeal cancer in Hong Kong, China.

Zhitongcaijing · 10/15 09:17
Zhitong Finance App News, Junshi Biotech (688180.SH) announced that Topuaili Biopharmaceutical Hong Kong Co., Ltd., a wholly-owned subsidiary of the company, has obtained the “Drug/Product Registration Certificate” issued by the Hong Kong Pharmacy and Poison Administration (“PPB”), and treprilimab (Hong Kong, China trade name: LOQTORZI®) combined with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent advanced nasopharyngeal cancer, and as a monotherapy for the recurrence and non-recurrence of disease progression after prior platinum-containing treatment or treatment or metastatic nasopharyngeal cancer The marketing license application for adult patients has been approved by PPB, and treprilizumab became the first and only tumor immunotherapy for nasopharyngeal cancer in Hong Kong, China.